News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Antisoma PLC Starts Phase I Clinical Trial of AS1409 in Renal Cancer and Melanoma
February 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON--(Marketwire - February 21, 2008) - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces the entry of AS1409 into clinical trials. A phase I trial has started in patients with renal cancer and melanoma.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Europe
MORE ON THIS TOPIC
Neuroscience
Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins
July 14, 2025
·
2 min read
·
Tristan Manalac
Depression
After Three Strikes, Relmada Abandons Depression Drug Esmethadone
July 14, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH ECLIPSEBIO
The mRNA Revolution You Haven’t Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
July 10, 2025
·
1 min read
·
Lori Ellis
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
